The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

The Pharma Data

JANUARY 25, 2021

The cocktail reduced viral load “with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline,” the researchers said. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

JANUARY 11, 2021

Speaking to the Reuters Next conference, Dale Fisher, chairman of the World Health Organization’s (WHO) Outbreak Alert and Response Network, said that achievement of herd immunity in most countries is unlikely in 2021.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Immune response was measured using immunoglobulin G (IgG) assays. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

APRIL 15, 2022

In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

JANUARY 22, 2021

The Weinreich article also reports that the “antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

AUGUST 6, 2020

Under the pact, AZ will transfer the vaccine’s technology to BioKangtai, which will in return reserve enough capacity to make at least 100 million doses of the shot by the end of 2020 and expand to 200 million doses per year by the end of 2021. Financial terms were not disclosed. Before the BioKangtai tie-up, it promised to provide the U.S.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

JANUARY 19, 2021

With this kind of a start, 2021 may be scorching. The company is working on a new approach to immunotherapy that uses the body’s own T-cells to create specific, potent, and durable immune responses for cancer and other life-threatening immune-mediated disease. TCR2 Therapeutics – The Cambridge, Mass.

Small Molecule 52

Small Molecule Laboratories Immune Response Trials 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ).

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. FDA for ITP.

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

Drug Discovery World

JULY 17, 2023

Unravelling the influence of these gut bacteria—commonly referred to as the bacterial gut microbiome—on drug response and immune response will bring fundamental changes to how we approach drug discovery and development, as well as patient care. REFERENCES Rosshart, S. Science (80-. ). 365, (2019) .

Immune Response 130

Immune Response Drugs Drug Development Drug Research 130

The Pharma Data

JANUARY 20, 2021

20, 2021 /PRNewswire/ — INOVIO Pharmaceuticals, Inc. The offering is expected to close on or about January 25, 2021 , subject to customary closing conditions. PLYMOUTH MEETING, Pa. , This offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

DNA 40

DNA Immune Response Disease Clinical Trials 40

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . There is hope that Moderna’s vaccine could be available by early 2021. . Each patient was given two 100 microgram doses of the vaccine 28 days apart.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

Drug Discovery World

FEBRUARY 13, 2023

Diseases ranging from cancer to viral immune response, from cardiovascular to reproductive health, and from metabolic to nervous systems all have the potential to benefit from in-depth transcriptomics. since October 2021. HTG’s RNA profiling technology has been featured in hundreds of peer-reviewed publications in this area.

RNA 130

RNA Drugs Immune Response Therapies 130

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response.

Virus 52

Virus Immune Response Vaccine Research 52

Drug Target Review

JANUARY 15, 2024

The preclinical results demonstrated significant immune responses and tumour regression. Could you elaborate on the mechanisms by which these responses are initiated within cancer cells? 2021 May 7;0(0). The concept of the ‘abscopal effect’ in the 4T1 tumour model is intriguing. Reference 1. Cell [Internet].

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

The Pharma Data

NOVEMBER 23, 2021

A team of researchers led by the University of Zurich (UZH) has now discovered another component that contributes to SARS-CoV-2 immunity – previous antibody responses to other, harmless coronaviruses. But even though the protection isn’t absolute, cross-reactive immune responses shorten the infection and reduce its severity.

Immune Response 52

Immune Response Vaccine Virus Hospitals 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. If results are positive, Phase 3 study to start in Q2 2021, with vaccine expected to be available in Q4 2021. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. The company, along with partners University of Nottingham and Trent University, received a British government grant to support the study. .

Clinical Trials 52

Clinical Trials Pharma Companies Vaccine Trials 52

The Pharma Data

JANUARY 22, 2021

22, 2021 — Not many people have had the opportunity to get the COVID-19 vaccine yet. An Ohio State University review of 49 vaccine studies dating back 30 years examined how stress, depression and healthy behaviors, such as exercise, can affect immune response to a vaccine. ” © 2021 HealthDay. FRIDAY, Jan.

Immune Response 52

Immune Response Vaccine Research Science 52

The Pharma Data

MAY 12, 2021

New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders. Additional data to be shared on rilzabrutinib, an investigational, peripheral Bruton’s tyrosine kinase (BTK) inhibitor with Tailored Covalency ® technology intended to treat immune thrombocytopenic purpura (ITP).

Disease 40

Disease FDA Treatment Therapies 40

The Pharma Data

JANUARY 31, 2021

1, 2021 12:05 UTC. Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). ATLANTA–( BUSINESS WIRE )– Virios Therapeutics, Inc.

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

JANUARY 9, 2021

9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. But such patients should be warned of the possibility that they will have a lower immune response. © 2021 HealthDay. . © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Immune Response Doctors Disease 52

The Pharma Data

DECEMBER 8, 2020

With the proceeds, Qu Biologics will complete stage 1 of the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease and its Phase 2 Study to assess activation of anti-cancer immune response in colon cancer. “We

Immune Response 52

Immune Response Clinical Trials Disease Production 52

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed. About Novavax.

Government 52

Government Vaccine Immune Response Clinical Trials 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. 21, 2021, online.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% However, Europe is facing increasing competition from emerging economies.

Drugs 147

Drugs Molecular Biology Science Clinical Trials 147

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Discovery World

APRIL 20, 2023

SARS-CoV-2 particles spread through the respiratory mucosa and other infected cells, causing changes in peripheral immune cells and eliciting a cascade of immune responses, resulting in a detrimental cytokine storm. 2021, doi: 10.1038/ s41598-021-92045-x. 2021, doi: 10.1016/j.eclinm.2021.101019. S Bliddal et al.,

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

SEPTEMBER 2, 2020

The randomised, double blind and placebo-controlled trial is designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the experimental COVID-19 vaccine candidate. If successful, the companies intend to request regulatory approval in the first half of 2021.

Vaccine 52

Vaccine Trials Immune Response Clinical Trials 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon. Jason Scott. Source link.

Vaccine 52

Vaccine Immune Response Clinical Trials Trials 52

The Pharma Data

JANUARY 12, 2021

Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 4, 2021

4, 2021 — As U.S. “The goal of vaccinating 100 million people in the first 100 days [of 2021] is a realistic goal,” Fauci added. “There is a path forward if you can show that two lower doses yield a similar immune response,” Dean said. © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

The Pharma Data

JANUARY 22, 2021

22, 2021 — British Prime Minister Boris Johnson warned on Friday that a new, more infectious coronavirus variant first spotted in the United Kingdom late last year could also be more lethal. “This is the first time I’ve been concerned about a variant partially evading the immune response and partially evading the vaccine.”

Vaccine 52

Vaccine Virus Immune Response Government 52

The Pharma Data

DECEMBER 23, 2020

Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021. Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com. About TREM-1 pathway.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52